Cardiovascular Safety of the β3 -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial-Reference-Cited by-同舟云学术

Cardiovascular Safety of the β3 -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial

Published:2018-04-12 Issue:8 Volume:58 Page:1084-1091
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

White William B.¹^ORCID,Chapple Christopher²,Gratzke Christian³,Herschorn Sender⁴,Robinson Dudley⁵,Frankel Jeffrey⁶,Ridder Arwin⁷,Stoelzel Matthias⁷,Paireddy Asha⁷,van Maanen Robert⁷,Weber Michael A.⁸

Affiliation:

1. Calhoun Cardiology Center; University of Connecticut School of Medicine; Farmington CT USA

2. Royal Hallamshire Hospital; University of Sheffield; Sheffield UK

3. Department of Urology; University of Munich; Munich Germany

4. Sunnybrook Health Sciences Centre; University of Toronto; Toronto Ontario Canada

5. King's College Hospital; London UK

6. Seattle Urology Research Center; Seattle WA USA

7. Department of Data Science; Astellas Pharma Global Development; Leiden Netherlands

8. Division of Cardiovascular Medicine; State University of New York Downstate Medical Center; Brooklyn NY USA

Funder

Astellas Pharma Europe B.V

Astellas Pharma Global Development

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference42 articles.

1. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study;Coyne;BJU Int.,2009

2. Economic burden of urgency urinary incontinence in the United States: a systematic review;Coyne;J Manag Care Pharm.,2014

3. Gender differences in overactive bladder;Eapen;Can J Urol.,2016

4. Global prevalence and economic burden of urgency urinary incontinence: a systematic review;Milsom;Eur Urol.,2014

5. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder;Andersson;BJU Int.,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis;Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics;2023-06

2. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults;Cochrane Database of Systematic Reviews;2023-05-09

3. A randomized controlled trial study on effectiveness between tadalafil versus combination mirabegron and solifenacin on treatment of ureteral stent-related symptoms;Pan African Medical Journal;2023

4. Mirabegron in the Management of Overactive Bladder Syndrome;International Journal of Women's Health;2022-09

5. Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder;Medicina;2022-06-19